2013;7:29 34. S4.4.6.2-11. Zhang Z-N, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. 2011;97:1876 81. S4.4.6.2-12. Garg N, Tripathy N, Sinha N. Comparative efficacy of sildenafil in Eisenmenger s syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. Cardiol Young. 2011;21:631 8. S4.4.6.2-13. Tay ELW, Papaphylactou M, Diller G-P, et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol. 2011;149:372 6. S4.4.6.2-14. Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 in- hibitor tadalafil in pulmonary arterial hypertension. Indian Heart J. 2007;59:323 8. S4.4.6.2-15. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a pre- liminary observational study. Circulation. 2006;114:1807 10. S4.4.6.2-16. Singh TP, Rohit M, Grover A, et al. A randomized, placebo-con- trolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1 851.e5. S4.4.6.2-17. Gali N, Hoeper MM, Humbert M, et al. Guidelines for the diag- nosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2009;30:2493 537. S4.4.6.2-18. D Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil associa- tion in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155:378 82. 4.4.7. Coronary Anomalies S4.4.7-1. Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active sur- veillance. J Am Coll Cardiol. 2011;58:1254 61. S4.4.7-2. Krasuski RA, Magyar D, Hart S, et al. 